Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share

Rhea-AI Summary

Sinovac Biotech (NASDAQ: SVA) shareholder Heng Ren Partners has sent a follow-up letter to Sinovac's Board on April 8, 2025, demanding disclosure of record and payment dates for the previously announced $55 per share special cash dividend. The letter also urges for an additional dividend of $41 per share, which would bring the total distribution to $96 per share.

Heng Ren argues that even after the proposed total dividend distribution, Sinovac would retain over $1.3 billion in net cash, deemed sufficient for operations. The shareholder highlights concerns about the company holding excess cash, referencing a June 2023 SEC inquiry about distribution limitations. According to Heng Ren, Sinovac's current cash reserves could finance nearly nine years of capital expenditures, even without revenue or operating cash flow.

Positive

• Announced special cash dividend of $55 per share
• Company has substantial cash reserves of over $6.3 billion
• No restrictions or limitations identified for distributing earnings to investors

Negative

• Trading of shares remains halted on Nasdaq
• Company holding excessive cash without clear business justification
• Lack of transparency regarding dividend record and payment dates
• No response to previous shareholder communications from March 19, 2025

BOSTON, April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025.  More than a week after the dividend announcement, these simple and essential details oddly remain undisclosed.  Heng Ren previously sent the Board a letter on March 19, and received no response.  The April 8 letter urges Sinovac to pay an additional dividend of $41 per share, which would pay shareholders a total of $96 per share and leave Sinovac with more than $1.3 billion net cash on hand – an amount more than sufficient for Sinovac's operating needs.  Heng Ren encourages like-minded shareholders to visit https://www.hengreninvestment.com/sinovac-fairness/ and contact Sinovac directly.

The full text of the letter follows:

April 8, 2025

Dear Board of Directors:

I write on behalf of Heng Ren regarding our March 19, 2025 Shareholder Demand for Cash Distribution and Inspection of Books and Records (the "Shareholder Demand") and the Company's press release dated April 1, 2025 (the "Press Release"), in which the Board announced a special cash dividend of US$55.00 per common share (the "Dividend").¹  Specifically, the Press Release stated that the Board expects to "fund the Dividend from available cash resources of the Company and its subsidiaries, including prior distributions from Sinovac Life Sciences Co., Ltd. and other operating subsidiaries of the Company."  Heng Ren also notes that the Board announced that the "Dividend is intended to provide [Company] shareholders with their appropriate share of these prior distributions from the Company's subsidiaries."

Heng Ren is encouraged that the Board has announced the Dividend, which is consistent with its fiduciary obligations to allow shareholders finally to receive some benefit of their investment in Sinovac.  But more is required.  In order to increase transparency and trust, and ensure that Sinovac shareholders receive the benefit of their investment, the Board must immediately disclose the exact timing of the record and payment dates, and mechanics for the payment of the announced Dividend. This disclosure is especially critical given that shareholders still are unable to trade their shares due to the continued trading halt on the Nasdaq. The Board should also provide an update this week on the status of the resumption of trading of Sinovac's stock as it is of critical importance to all shareholders. 

Furthermore, even after paying the Dividend, the Company still will be holding more than $6.3 billion in net cash and cash equivalents.  We see no rational business reason for the Company to continue to sit on that much cash.  The time to distribute the cash is now.  Therefore, the Board must not only cause the Company to pay the Dividend, but also cause the Company to pay an additional special dividend of $41 per share.  Such a dividend payment would leave the Company with more than $1.3 billion net cash on hand, an amount well above its operating needs. 

The issue of excess cash and its distribution is not only a matter of interest to shareholders like us. It also is of interest to the U.S. Securities and Exchange Commission (SEC).  As Heng Ren referenced in its letter dated March 19, 2025, in the correspondence from the SEC's Division of Corporate Finance to Sinovac dated June 26, 2023, the SEC specifically asked the Company to describe "any restrictions and limitations on [its] ability to distribute earnings from the [C]ompany . . . to U.S. investors."  In response, Sinovac did not identify any limitations on its ability to make distributions to investors, but simply stated it had no intention of distributing dividends in the near future.  At that time, the Company was sitting on more than $10.0 billion in net cash or cash equivalents.  This action (or inaction) precluded Sinovac's shareholders from benefiting from the billions of dollars in cash that their investment had created.

Without a clear timeline on the payment of the announced $55 cash dividend, and Sinovac's problem of excess cash still unaddressed, from a shareholders' perspective the situation hasn't changed since 2023 when the SEC sent its inquiry to Sinovac.

As demonstrated by the Company's June 30, 2024 financial report, Sinovac's cash on hand – without any revenue or operating cash flow, and after distribution of the $55 cash dividend –would finance nearly nine years of capital expenditures.

Sinovac can responsibly distribute not only the $55 cash dividend, but an additional special dividend of $41 per share.  The board and shareholders all should be aligned and in agreement for the distributions. These distributions pale in comparison to the opportunity cost of Sinovac's shares being halted from trading when the Company's value peaked in 2021. Long-oppressed shareholders now are entitled to receive this cash.

Heng Ren reiterates its previous demand to inspect and to make copies or extracts from, the books and records set forth in Section II.C (Parts 1-9) of its Shareholder Demand.

About Heng Ren:

Heng Ren Partners is a Boston-based asset management firm investing in Chinese companies.  Ropes & Gray LLP is serving as its legal counsel.

---

Any shareholder may obtain additional information or contact Heng Ren      at https://www.hengreninvestment.com and click "Sinovac Fairness."

¹ Capitalized terms undefined herein shall have the same meanings ascribed to them in the Shareholder Demand.

View original content:https://www.prnewswire.com/news-releases/heng-ren-partners-calls-on-sinovac-to-disclose-the-record-and-payment-dates-of-the-special-dividend-and-distribute-an-additional-dividend-of-41-per-share-302426041.html

SOURCE Heng Ren Partners

FAQ

What is the total dividend amount Heng Ren Partners is requesting from Sinovac (SVA)?

Heng Ren Partners is requesting a total dividend of $96 per share, comprising the announced $55 special dividend plus an additional $41 per share.

How much cash would Sinovac (SVA) retain after paying the proposed $96 per share dividend?

Sinovac would retain over $1.3 billion in net cash after paying the proposed total dividend of $96 per share.

Why is Heng Ren Partners demanding immediate disclosure of SVA's dividend dates?

The disclosure is critical because shareholders cannot trade their shares due to an ongoing trading halt on Nasdaq, making timing information essential for investors.

How long could SVA's current cash reserves fund capital expenditures?

According to the June 30, 2024 financial report, Sinovac's cash reserves could finance nearly nine years of capital expenditures without revenue or operating cash flow.